 |
| ||||||||||||||
 |
||||||||||||||
|
|
 |
| We are involved in non-clinical research to develop novel pharmaceuticals to treat cardiovascular diseases. We employ an integrative approach to study the effect of compounds on molecular, cellular and whole organ function. We devote great effort to establish and study compounds in disease models using state-of-the-art research techniques. |
| * OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989 |